Page last updated: 2024-08-21

pyrovalerone and Breast Neoplasms

pyrovalerone has been researched along with Breast Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Feng, J; Hu, X; Jiang, Z; Li, H; Li, W; Liu, Y; Ma, F; Ouyang, Q; Tong, Z; Wang, S; Xu, B; Yu, S; Zhu, X; Zou, J	1

Trials

1 trial(s) available for pyrovalerone and Breast Neoplasms

Article	Year
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-10, Volume: 37, Issue:29 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrrolidines; Receptor, ErbB-2; Taxoids; Trastuzumab	2019

Article

Year

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-10, Volume: 37, Issue:29

Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrrolidines; Receptor, ErbB-2; Taxoids; Trastuzumab

2019